A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Recognizing how persistent depressive disorder manifests and plays out in the lives of individuals is the first step in ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

Scientists at the National Center for Supercomputing Applications and the University of Illinois College of Medicine Peoria (UICOMP) were authors of a research paper published in the Journal of ...